"While market conditions across the year have not been favourable, its impact upon our performance has been mitigated to some extent by the depth of our product portfolio, customer base and sales operation,"
CML Managing Director Chris Gurry said.
Objective: To study the atypical BCR/ABL gene rearrangement patterns by Fluorescence in situ hybridization (FISH) in patients of
CML and to determine their clinico-haematological characteristics and response to treatment.
Hence, the novelty of the study would be to collect data on serum levels of
CML and sRAGE measured simultaneously among T2DM with ACS.
Strong Ownership and Support: Under Fitch's Government-Related Entities (GRE) Rating Criteria, we assess
CML's status, ownership and control by the government as 'Strong'.
There is no known cause for the genetic change that results in
CML.
Keywords: Adverse effects,
CML, Imatinib, Patient-reported symptoms, Quality of life.
The blasts were positive for BCR-ABL1 by FISH and karyotyping (Figures 3(a) and 3(b)), with additional chromosomal abnormalities indicating clonal evolution of
CML with T-cell blast crisis.
Patients diagnosed with accelerated and blast phase of
CML has a bad response while treatment only using TKIs.
The diagnosis of
CML in the chronic phase was made.
The sequential occurrence of
CML and MCL has been reported.
Additional content reinforces the value of mutation testing as a standard practice in monitoring patients with
CML, including its importance for identifying the risk of treatment resistance.